Cumberland Pharmaceuticals Inc (CPIX) Stock AnalysisCPIXStock AnalysisCumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, and Tacilia (omeprazole, amoxicillin and rifabutin) an oral capsule. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cumberland Pharmaceuticals Inc (CPIX) appears to be a good buy right now due to its current price of $8.46, which is near its recent 52-week high of $8.45, supported by a strong 5-day price change of +10.59% and a year-to-date change of +112.56%. The company has also announced a special dividend of $1.50 per share, reflecting a commitment to shareholder returns. However, the main risk is its negative net income of -3.1 million in Q2 2026, which indicates ongoing financial challenges.

1 analysts cover CPIX: 0 rate it Buy, 1 Hold and 0 Sell.